New York, NY (October 31, 2017) –The U.S. Food and Drug Administration (FDA) announced it has approved the use of obinutuzumab (Gazyva®) to treat patients with previously untreated advanced follicular lymphoma (FL). Under the new indication, patients with stage II…
New York, NY (November 9, 2017) –The U.S. Food and Drug Administration (FDA) announced it has approved the use of brentuximab vedotin (ADCETRIS®) to treat patients with certain types of cutaneous T-cell lymphoma (CTCL) who have received at least one…
New York, NY (October 31, 2017) –The U.S. Food and Drug Administration (FDA) announced it has approved the use of acalabrutinib (CALQUENCE) to treat patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. The Bruton…
NYC Law Firm Set to Receive LRF Award at 2017 North American Educational Forum on Lymphoma in Brooklyn New York, NY (October 20, 2017) –The Lymphoma Research Foundation (LRF) – the nation’s largest non-profit organization devoted exclusively to funding innovative…
Hundreds of Lymphoma Patients and Loved Ones Set to Attend Nation’s Most Comprehensive Lymphoma Education Program New York, NY (October 5, 2017) –The Lymphoma Research Foundation (LRF) – the nation’s largest non-profit organization devoted exclusively to funding innovative lymphoma research…
LRF Hosts Hundreds at “Powered by Innovation” Themed Gala at the Historic Plaza Hotel in New York City New York, NY (October 5, 2017) –The Lymphoma Research Foundation (LRF) – the nation’s largest non-profit organization devoted exclusively to funding innovative…
The work of a physician-scientist is wholly unique: doggedly pursuing innovative research to find new treatments for the patients in their care. It is a calling; as much a vocation as a career path. Perhaps no one embodied that calling…
A Night “Powered by Innovation” Set to Culminate Blood Cancer Awareness Month in September New York, NY (September, 2017) –The Lymphoma Research Foundation (LRF) – the nation’s largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the…
New York, NY (September 14, 2017) – The U.S. Food and Drug Administration (FDA) announced it has approved the use of copanlisib to treat patients with relapsed indolent follicular lymphoma (FL). The PI3K dual-isoform inhibitor, developed by Bayer, has been…
